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Alun D. Hughes, MBBS, PHD,s Darrel P. Francis, MDaABSTRACTISSOBJECTIVES BRAVO (British Randomized Controlled Trial of AV and VV Optimization) is a multicenter, randomized,
crossover, noninferiority trial comparing echocardiographic optimization of atrioventricular (AV) and interventricular
delay with a noninvasive blood pressure method.
BACKGROUND Cardiac resynchronization therapy including AV delay optimization confers clinical beneﬁt, but the
optimization requires time and expertise to perform.
METHODS This study randomized patients to echocardiographic optimization or hemodynamic optimization using
multiple-replicate beat-by-beat noninvasive blood pressure at baseline; after 6 months, participants were crossed over to
the other optimization arm of the trial. The primary outcome was exercise capacity, quantiﬁed as peak exercise
oxygen uptake. Secondary outcome measures were echocardiographic left ventricular (LV) remodeling, quality-of-life
scores, and N-terminal pro–B-type natriuretic peptide.
RESULTS A total of 401 patients were enrolled, the median age was 69 years, 78% of patients were men, and the
New York Heart Association functional class was II in 84% and III in 16%. The primary endpoint, peak oxygen uptake,
met the criterion for noninferiority (pnoninferiority ¼ 0.0001), with no signiﬁcant difference between the hemodynamically
optimized arm and echocardiographically optimized arm of the trial (mean difference 0.1 ml/kg/min). Secondary
endpoints for noninferiority were also met for symptoms (mean difference in Minnesota score 1; pnoninferiority ¼ 0.002)
and hormonal changes (mean change in N-terminal pro–B-type natriuretic peptide -10 pg/ml; pnoninferiority ¼ 0.002).
There was no signiﬁcant difference in LV size (mean change in LV systolic dimension 1 mm; pnoninferiority < 0.001;
LV diastolic dimension 0 mm; pnoninferiority <0.001). In 30% of patients the AV delay identiﬁed as optimal was more than
20 ms from the nominal setting of 120 ms.
CONCLUSIONS Optimization of cardiac resynchronization therapy devices by using noninvasive blood pressure is
noninferior to echocardiographic optimization. Therefore, noninvasive hemodynamic optimization is an acceptable
alternative that has the potential to be automated and thus more easily implemented. (British Randomized
Controlled Trial of AV and VV Optimization [BRAVO]; NCT01258829) (J Am Coll Cardiol Img 2018;-:-–-)
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
AV = atrioventricular
CI = conﬁdence interval
CRT = cardiac
resynchronization therapy
LV = left ventricular
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
VV = ventriculoventricular
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2D elivering cardiac resynchronizationtherapy (CRT) to appropriatelyselected patients causes immedi-
ate improvements in cardiac function. The
early studies observed immediate improve-
ments in hemodynamic parameters (1–3),
including peak rates of rise of intraventric-
ular pressure (4), stroke volume (5), and
blood pressure (4,6). Subsequent studies
revealed improvements in exercise capacity,
left ventricular (LV) volumes, quality of
life (7–9), and N-terminal pro–B-type natri-uretic peptide (NT-proBNP) values (10). Finally, large,
randomized, long-term studies demonstrated reduc-
tions in hospitalizations and mortality (11,12).
The beneﬁcial effects of CRT stem ultimately
from the changes in timing of cardiac activation.
The landmark CARE-HF (CArdiac REsynchronisation
in Heart Failure) trial performed atrioventricular (AV)
delay optimization after device implantation by
using echocardiography. Echocardiography remains
the most commonly recommended method for opti-
mization (13,14). In this process the AV delay is set
to maximize separation of the E and A waves on
transmitral Doppler imaging. The precise AV and
ventriculoventricular (VV) delays that maximize
hemodynamic measurements vary among patients,
perhaps because of the complexity of the disease and
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FIGURE 1 Flowchart of Study Design
Follow up after 6 months
Exercise Test, Echocardiogram, Bloods, QoL
Follow up after 12 months
Exercise Test, Echocardiogram, Bloods, QoL
1:1 Randomization visit
Echocardiographic
optimum
Hemodynamic
optimum
Echocardiographic
optimum
Hemodynamic
optimum
Screening
ECG, anthropometrics, QoL
Patients visited 4 times and underwent 2 atrioventricular and interventricular delay
optimizations according to echocardiographic and hemodynamic protocols.
ECG ¼ electrocardiography; QoL ¼ quality of life.
TABLE 1 Inclusion and Exclusion Criteria
Inclusion Criteria Exclusion Criteria
Previous diagnosis of chronic heart failure Major cardiovascular event within
6 weeks before enrollment
Cardiac resynchronization therapy device
implanted at least 6 months before
enrollment
Uncontrolled hypertension
History of symptomatic congestive
heart failure (NYHA functional class II–IV)
Inability to walk on treadmill
Prior ejection fraction <40% or documented
moderate to severely impaired systolic
dysfunction
Stable medical therapy for heart failure
>90% biventricular pacing
NYHA ¼ New York Heart Association.
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3with the passage of time in response to spontaneous
physiological processes. In addition, when settings
are changed to improve cardiac output there is a
resulting reﬂex fall in peripheral resistance that
returns the blood pressure toward the mean, even
though improvements in cardiac output remain (15).
It is therefore better to sample blood pressure before
this occurs.
The BRAVO (British Randomized Controlled Trial
of AV and VV Optimization) trial tested the hypoth-
esis that physiological optimization of AV and VV
delay would be noninferior to echocardiographic
optimization.
METHODS
STUDY DESIGN. The design (21) was a crossover
trial that was prospective, randomized, and open with
blinded evaluation of endpoints. Analysis of cardio-
pulmonary exercise test data, echocardiography, and
blood results was performed by investigators blinded
to the study arm.
Patients were recruited from 19 centers in the
United Kingdom. Patients were randomly allocated to
an optimization method using an online system.
They were followed up for 6 months and then crossed
over to the other optimization method for a further
6 months of follow-up (Figure 1).
INCLUSION AND EXCLUSION CRITERIA. Study
inclusion and exclusion criteria are shown in Table 1.
OPTIMIZATION OF AV ANDVV DELAY. We performed
echocardiographic optimization of the AV delay using
Doppler echocardiography of transmitral ﬂow by
using the iterative method as used in the CARE-HF
trial (22). VV delay optimization was performed by
maximizing aortic outﬂow tract aortic Doppler
measurements.
Hemodynamic optimization of AV and VV delay was
performed using multibeat averages acquired through
noninvasive blood pressure measured using the Fin-
ometer device (Finapres Medical Systems, Amster-
dam, the Netherlands). To obtain a narrow conﬁdence
interval (CI) we used a speciﬁc algorithm (23). This
performs multiple alternations between a tested and
reference AV delay and calculates the mean relative
change in systolic blood pressure. It closely mirrors
invasive optimization (24). We ﬁrst calculated the AV
optimum, and then we determined the VV optimum at
that AV delay. Some previous studies have used LV dP/
dt max as a target for maximization. The BRAVO trial
used systolic blood pressure because this can be ac-
quired noninvasively or invasively with equal preci-
sion, and it reﬂects the external consequences of
cardiac function. We have previously shown that thismethod is highly reproducible (25). Its noninvasive
nature permits large numbers of replicates, which
narrow the CI of the estimated optimum (26). Each
hemodynamic optimization (Figure 2) took approxi-
mately 20 min, with a further 10 min for off-line anal-
ysis. This time could be shortened in the future if the
process were automated. When patients were in atrial
ﬁbrillation (AF), only VV optimization was performed.
Patients with AF were included because if cardiac
resynchronization indeed works by resynchronizing
the ventricles, as is generally supposed, then the
FIGURE 2 Simpliﬁed Schematic of Hemodynamic Optimization Method
Step 1. Multiple
replicate
measurements of
BP of tested
setting against
reference setting
Step 2. Average
change in BP
relative to
reference setting
plotted against VV
delay
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AV optimization
curve:
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Continuous noninvasive beat-to-beatmeasurements aremade through the Finometer (FinapresMedical Systems, Amsterdam, theNetherlands).
Multiple alternations are carried out between a tested atrioventricular (AV) or ventriculoventricular (VV) delay and reference AV or VV delay.
Blood pressures (BPs) before and after a transition in pacing state are measured as an average of 8 to 10 beats, as previously described (16). The
average change in BP is plotted against AV or VV delay to ﬁt a curve. The peak of the curve is used to select the optimum. LV¼ left ventricular.
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4interventricular timing should continue to be as
important in AF as it is in sinus rhythm.
ENDPOINTS. The primary endpoint was objective
exercise capacity deﬁned as peak oxygen uptake on
cardiopulmonary exercise testing (27). To ensure
standardization, all exercise tests were carried out at
1 of 2 sites that are experienced in performing this
testing. Secondary outcome measures were LV
reverse remodeling, as assessed by echocardiographicLV dimensions (LV end-diastolic dimension and LV
end-systolic dimension), NT-proBNP, and quality of
life, assessed using standardized scores for heart
failure: the 36-Item Short Form Health Survey version
2 (28) and the Minnesota Living with Heart Failure
questionnaire score (29).
STUDY CONDUCT AND REGULATORY ISSUES. The
study was compliant with good clinical practice
guidelines and with the most recent version of the
TABLE 2 Baseline Characteristics (n ¼ 401)
Age, yrs 67  12.7
Median 69
Male 78
NHYA functional class
I 0.3
II 84
III 16
IV 0
CRT-P 36
CRT-D 64
Systolic blood pressure, mm Hg 121  21
Diastolic blood pressure, mm Hg 69  11
Atrial ﬁbrillation 12
Creatinine, mmol/l 112  40
Pharmacotherapy
ACE inhibitor or angiotensin-receptor blocker 49
Beta-blocker 69
Diuretic agent 56
Mineralocorticoid receptor antagonist 43
Digoxin 19
Values are mean  SD or %.
ACE ¼ angiotensin-converting enzyme; CRT-D ¼ cardiac resynchronization
therapy deﬁbrillator; CRT-P ¼ cardiac resynchronization therapy pacemaker.
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5Declaration of Helsinki. The studywas approved by the
South West London Research Ethics Committee (3),
and site-speciﬁc assessments were performed for
each participating hospital. All patients gave prior
written informed consent. The trial was registered
with ClinicalTrials.gov (NCT01258829).
STATISTICS. Distributions are described by their
mean  SD. NT-proBNP is expressed as log10
NT-proBNP because it has a positive skew. Comparison
between arms of the trial was performed by paired
Student’s t-test. Analysis was restricted to patients
with before and after data for that variable. Differences
between arms of the study are expressed as mean and
95% CI. The noninferiority margin for peak oxygen
uptake (primary endpoint) was 0.75 ml/kg/min, for the
Minnesota Living with Heart Failure score it was 4
points, for the 36-Item Short Form Health Survey
version 2 physical component score it was 8.5, for NT-
proBNP it was a fall of 0.062 log units (i.e., approxi-
mately a 13%decrease), for LV end-diastolic dimension
it was 2 mm, and for LV end-systolic volume it was 2
mm. pnoninferiority was calculated for these variables
against their respective noninferiority margins.
The study sample size was chosen to have
90% power to detect a margin of equivalence of
0.75 ml/kg/min at the 5% signiﬁcance level, on the
basis of a published reproducibility of 2.4 ml/kg/min
(30). On this basis, 177 participants per arm of the trial
were required.
RESULTS
A total of 401 patients met the enrollment criteria and
gave informed consent to participate in the BRAVO
trial. Baseline characteristics are displayed in Table 2.
Patients’ ﬂow and study withdrawals are illustrated
in Figure 3. A total of 22 patients did not undergo
randomization; 379 patients were randomized, and
48 had AF.
There were 12 deaths, 7 during the echocardio-
graphic arm and 5 during the hemodynamic arm.
Another 33 patients withdrew from the study because
of deterioration in heart failure symptoms or were
lost to follow-up, 14 during the echocardiographic
arm and 19 during the hemodynamic arm.
Nine patients experienced adverse events unre-
lated to heart failure that led to withdrawal from the
study. Six of these patients had device-related prob-
lems (device erosion requiring extraction or loss of LV
lead capture, 1 where the settings were changed at
another hospital), and 3 patients had other adverse
events (1 stroke, 1 myocardial infarction, 1 aneurysm).
A further 31 patients withdrew for speciﬁc reasons
that were not a deterioration in heart failure. Theseconditions included musculoskeletal deterioration,
peripheral neuropathy, deterioration in balance, torn
knee ligaments, depression, terminal cancer, leg ul-
cers, and stroke. A total of 39 patients completed all
the study visits but were unable to complete both
exercise tests. See Online Table 1 for baseline char-
acteristics of the participants who did not compete
both arms of the trial.
COMPARISON OF HEMODYNAMIC OPTIMIZATION WITH
ECHOCARDIOGRAPHIC OPTIMIZATION. Cardiopulmonary
exercise testing. A total of 250 patients completed
the entire 12-month study protocol and performed
cardiopulmonary exercise testing after both echo-
cardiographic and hemodynamic optimization.
The results met the primary pre-speciﬁed non-
inferiority criteria (pnoninferiority ¼ 0.0001). There
was no signiﬁcant difference in peak oxygen
uptake with noninvasive hemodynamic optimization
compared with echocardiographic optimization, with
a mean difference of 0.1 ml/kg/min (95% CI: 0.25
to þ0.41 ml/kg/min) (Figure 4, Table 3).
No signiﬁcant difference was observed in the
minute ventilation/carbon dioxide production slope,
with a mean difference of 0.3 (95% CI: 0.6 to þ1.2;
p ¼ 0.2). There was also no difference in exercise
duration, with a mean difference of 0.02 min
(95% CI: 0.26 to þ0.21 min; p ¼ 0.76). See also
Online Table 2 for the statistics for order effects.
Left ventricular dimension. Differences in end-systolic
and end-diastolic dimensions between the 2 arms
FIGURE 3 Patient Flow
379 Patients Randomized
401 Patients Consented
289 completed both arms
39 patients completed the study but did not perform
both cardiopulmonary exercise tests
(due to non-heart failure related reasons)
Primary endpoint data available for 250 patients
Randomized to
Hemodynamic
Optimization
Randomized to
Echocardiographic
Optimization
Randomized to
Echocardiographic
Optimization
Randomized to
Hemodynamic
Optimization
Reasons for withdrawals
during Hemodynamic
arm:
5 deaths
19 due to HF
deterioration or loss
to follow up
3 due to change in
symptoms following
optimization
4 device related (lead issues)
1 stroke
1 aneurysm
1 acute coronary
syndrome
16 withdrawals due
to non-cardiac
reasons
Total 50
•
•
•
•
•
•
•
•
•
Reasons for withdrawals
during Echo arm:
7 deaths•
14 due to HF
deterioration or loss
to follow up
•
2 due to change in
symptoms following
optimization
•
2 device related
(1 explant, 1 change in
settings)
•
15 due to non-cardiac
reasons
•
Total 40•
Patients were randomized to either optimization method for 6 months before crossing over to the other arm of the trial for a further 6 months.
Investigations performed at each stage are listed. HF ¼ heart failure.
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6(n ¼ 284) met criteria for noninferiority, with a mean
difference in LV systolic dimension of 1 mm (95%
CI: 1.5 to 0.4 mm; pnoninferiority < 0.0001) and a mean
difference in LV diastolic dimension of 0 mm (95%
CI: 0.8 to 0.9 mm; pnoninferiority < 0.0001).
Quality of life. 36-Item short form health survey version 2.
Differences in the symptoms measured by the phys-
ical component score of the 36-Item Short Form
Health Survey version 2 after 6 months of treatment
with hemodynamic optimization compared with
6 months of treatment with echocardiographic
optimization met the criteria for noninferiority, with
a mean difference of 0.30 (95% CI: 0.4 to 1.0;
pnoninferiority <0.001; n ¼ 269).
Minnesota questionnaire. Differences in the symp-
toms measured by Minnesota Living With Heart
Failure questionnaire score after after 6 months of
treatment with hemodynamic optimization compared
with 6 months of treatment with echocardiographic
optimization met the criteria for noninferiority, with
a mean difference of 1.05 (95% CI: 0.72 to 2.90;
pnoninferiority ¼ 0.002; n ¼ 268).
N-terminal pro–B-type natriuretic peptide. Differences in
the NT-proBNP after 6 months of treatment with he-
modynamic optimization compared with 6 monthstreatment with echocardiographic optimization met
the criteria for noninferiority, with a mean difference
of 10 pg/ml (95% CI: L180 to 200 pg/ml; pnoninferiority
< 0.002; n ¼ 262).
COMPARISON OF THE AV DELAY DETERMINED AS
OPTIMAL. For the atrial-sensed mode, the AV
optimum deﬁned by echocardiography averaged
122  32 ms, and by hemodynamic optimization it was
133  29 ms (difference of 11 ms; p < 0.0001).
COMPARISON OF VV DELAY DETERMINED AS
OPTIMAL. The VV delay identiﬁed as optimal using
the hemodynamic method averaged 0  22 ms, and by
echocardiography it was LV ﬁrst 2  34 ms (difference
of 2 ms; p ¼ 0.4) (Online Figure 1).
DISCUSSION
The primary endpoint of exercise capacity was non-
inferior to hemodynamic optimization compared with
echocardiographic optimization. The secondary
endpoints of LV dimensions, quality of life, and
NT-proBNP were also not signiﬁcantly different
between the 2 methods. These ﬁndings suggest that
hemodynamic optimization is an acceptable alterna-
tive to the established echocardiographic method.
FIGURE 4 Primary Outcome: Change in DVO2max, Shown as Mean With
95% Conﬁdence Interval
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Hemodynamic optimization using beat-to-beat noninvasive blood pressure
was noninferior to the conventional established method of echocardio-
graphic optimization. DVO2max ¼ change in peak oxygen uptake.
TABLE 3 Outcome Markers in the 2 Arms of the Study*
Echocardiographic
Optimization SD
Hemodynamic
Optimization SD Difference n
MLWHFQ score 36 24 37 24 1.0 268
SF36v2 physical
component score
38 10 39 10 1.0 269
LVEDD, mm 58 11 58 9 0 284
LVESD, mm 49 12 48 11 1.0 284
Peak VO2, ml/kg/min 14.5 4.5 14.6 4.7 0.1 250
NT-proBNP, pg/ml 1,338 2,585 1,348 2,723 10.0 262
Log10 NT-proBNP, log10 pg/ml 2.8 0.6 2.8 0.6 0 262
*Scores (with SD) are listed for all the primary and secondary outcomes measures for the study following
6 months of randomization in each arm.
LVEDD ¼ left ventricular end-diastolic dimension; LVESD ¼ left ventricular end-systolic dimension;
MLWHFQ ¼ Minnesota Living With Heart Failure questionnaire; NT-proBNP ¼ N-terminal pro–B-type natriuretic
peptide; SD ¼ standard deviation; SF36v2 ¼ 36-Item Short Form Health Survey version 2; VO2 ¼ oxygen uptake.
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7HEMODYNAMIC OPTIMIZATION. In the trials that
showed a survival beneﬁt from biventricular pacing,
COMPANION (Comparison of Medical Therapy,
Pacing, and Deﬁbrillation in Heart Failure) (12) and
CARE-HF (22), AV delay optimization was part of the
protocol. In clinical practice, however, echocardio-
graphic optimization has been difﬁcult to incorporate
routinely because it requires time and skills in both
pacemaker programming and echocardiography,
which sometimes require 2 staff members.
Optimizing with blood pressure (hemodynamics)
has the advantage of not requiring an expert to keep
an echocardiography probe correctly aligned.
More importantly, because pressure signals can be
quantiﬁed automatically, they do not require
human expertise to judge echocardiographic Doppler
waveforms. In fact, there is no technical barrier
to complete automation of the process of hemody-
namic optimization. With an appropriately implanted
hemodynamic sensor, the process can be carried out
automatically and repeatedly, at home.
AV AND VV OPTIMIZATION. This study was a
noninferiority study comparing echocardiographic
optimization of AV and VV delay with hemody-
namic optimization. Some studies have reported
that echocardiographic optimization improves out-
comes compared with nominal settings (31,32).
However, the SMART-AV (SmartDelay Determined
AV optimization: A Comparison to Other AV Delay
Methods Used in Cardiac Resynchronization Ther-
apy) trial found no signiﬁcant effect of optimization
of AV delay over nominal settings, after testing both
an echocardiographic method and an electrical
approach (33).
A potential explanation for the neutrality of the
SMART-AV trial is that inmany patients the optimal AV
delay is close to 120 ms, a common default value set by
manufacturers. In the BRAVO trial, the hemodynamic
optimization yielded a sensed AV delay optimum
that was within 20 ms of 120 ms in 70% of patients. For
echocardiographic optimization, the ﬁgure was similar
at 71%. (Figure 5). Because physiological responses are
approximately parabolic near the optimum (34), the
curve slopes are most shallow there, so small differ-
ences in AV delay near the optimum have only a rela-
tively small effect on physiology (23). This is reﬂected
in the BRAVO trial. Figure 5 shows that the distribution
in AV optima between the 2methods is different, but in
both cases w70% of the optima are within 20 ms of
120 ms. It is the w30% of patients whose optimal AV
delay is more than 20 ms from optimum who are likely
to have the most to gain from patient individualized
optimization.The modal AV optima are slightly shorter
with echocardiographic than with hemodynamic
optimization. However, the difference is small, at 40
ms. Because this occurs at the shallow portion of the
AV delay optimization curve, this difference will
produce only relatively small changes in cardiac
output. These small differences in cardiac output are
unlikely to be detected with the clinical outcome
measures we used in this study.
FIGURE 5 Distribution of AV Delay Identiﬁed as Optimal Using the 2
Optimization Methods
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In approximately one-third of patients, the optimal atrioventricular (AV) delay was found
to be more than 40 ms longer or shorter than the commonly used nominal setting of
120 ms. These patients are likely to have the most to gain from AV delay optimization.
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8The BRAVO trial was not designed to determine
whether hemodynamic optimization is superior to
nominal settings. To address this question, an
adequately powered study would need to be very
large because in 70% of patients the nominal AV delay
is within 20 ms of optimal. The parabolic nature of the
hemodynamic response to adjusting AV delay means
that small changes around the optimum have a rela-
tively small effect. Larger differences result in more
signiﬁcant changes in cardiac output because they
involve the steeper portion of the AV delay optimi-
zation curve.
Hemodynamic optimizations were performed at a
higher heart rate using atrial pacing rather than using
atrial sensing, to improve signal-to-noise ratio. Rather
than performing an optimization during atrial sensing,
we programmed the sensed AV delay 60 ms shorter
than the AV delay identiﬁed as optimal during atrial
pacing. It is possible that we would have identiﬁed a
different optimal-sensed AV delay had we performed
optimization during atrial sensing. However, usingthis protocol we found hemodynamic optimization to
be noninferior to echocardiographic optimization.
POTENTIAL PRACTICAL ADVANTAGES OF HEMO-
DYNAMIC OPTIMIZATION. Repeated optimization
carried out automatically by the pacemaker was
found in the CLEAR (Clinical Evaluation on Advanced
Resynchronization) (35) and RESPOND (Clinical Trial
of the SonRtip Lead and Automatic AV-VV Optimiza-
tion Algorithm in the PARADYM RF SonR CRT-D) (19)
studies to reduce heart failure hospitalizations in
comparison with 1-off optimization. In the CLEAR and
RESPOND studies a hemodynamic sensor made the
repeated autonomous optimizations possible. In the
BRAVO trial only a single optimization was carried
out in each arm of the trial. The hemodynamic opti-
mization method, however, does have the potential
for automatous repeat optimizations by the device
itself if it is combined with an appropriate sensor.
Our previous work has illustrated that the exact
choice of sensor is not as important as ensuring that
the protocol includes enough repetitions to deliver a
reproducible result. The BRAVO trial used a special-
ized beat-by-beat noninvasive blood pressure
monitor, but the same optimum is obtained if a sim-
ple pulse oximeter is used (with extra repetitions to
combat the extra noise) or if complex invasive arterial
monitoring is performed (36,37)
STUDY LIMITATIONS. The BRAVO trial enrolled pa-
tients who had undergone CRT implantation proced-
ures at least 6 months prior. The rationale was so the
relatively large therapeutic beneﬁt seen in the early
phase after CRT implantation would not obscure any
differences between the trial arms. Whether the re-
sults would have been different if randomization had
occurred shortly after device implantation is not
known.
In this study, there was a relatively high dropout
rate (24% of those randomized); 250 patients
completed both exercise tests. Of those participants
completing the study, 13% failed to have both exer-
cise tests performed. The numbers of dropouts do,
however, appear to be balanced between the groups.
The relatively long duration of participation in the
study, compared with other CRT studies, may explain
the high frequency of dropout. The most common
reason for dropout was an inability to carry out ex-
ercise testing for noncardiac reasons. Despite the high
dropout rate, the study still met the predeﬁned non-
inferiority threshold. This was because the midpoint
value of the result was so close to neutral that the
outer limit of the CI was well away from the non-
inferiority threshold.
This was a heterogeneous, “real-world” group of
patients with heart failure who came from a
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Noninvasive
hemodynamic optimization using beat-to-beat blood pressure
measurements is noninferior to widely used echocardiographic
methods used for optimization of biventricular pacemaker
optimization. This method is much less time consuming and less
labor intensive and can provide a much-improved experience
for patients.
TRANSLATIONAL OUTLOOK: This study did not set out
to determine whether hemodynamic optimization confers an
additional prognostic beneﬁt. A much larger study would be
required to determine this, and it is an area for further study.
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9spectrum of centers across the United Kingdom. This
study did not have a “run-in period” for optimiza-
tion of medical therapy because we wanted to test
this optimization protocol in real time. Given that
this was a crossover study, this was equally appli-
cable to both arms and would not have a net effect
on the question under investigation. The real-world
nature of this group is also reﬂected in a perceived
discrepancy in symptoms versus physiological
markers of heart failure severity. Most patients
included were in New York Heart Association func-
tional class II yet had a peak oxygen uptake in the
region of 14.5 ml/kg/min, which is more character-
istic of patients in New York Heart Association
functional class III.
The combined effect of echocardiographic AV and
VV delay optimization, compared with nominal set-
tings, has not been assessed in a randomized
controlled clinical trial. Our study cannot answer this
question because both arms of the trial had optimi-
zation performed: it shows that the hemodynamic
and echocardiographic approaches are equivalent on
the endpoints studied.
Our echocardiographic measurements were taken
with the participants in the lateral decubitus posi-
tion, and the hemodynamic measurements were
made with participants semirecumbent. Both mea-
surements were performed with the participants at
rest. Ideally, for a direct comparison both should be
performed in the same position, but these conven-
tional positions were used for comfort and optimal
data acquisition. Echocardiographic measurements
were performed only at a resting heart rate because
this is the conventional method described for
standard echocardiographic optimization.
CONCLUSIONS
The BRAVO trial demonstrates that the physio-
logical effectiveness of hemodynamically selected
AV and VV delay is not inferior to that ofechocardiographically selected AV and VV delay.
Noninvasive hemodynamic optimization is therefore
an acceptable alternative to echocardiographic opti-
mization, and it has the potential to be automated and
consequently more easily implemented.
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